S2 Therapeutics Inc., Santarus, VeroScience sales and marketing update

VeroScience and S2 granted Santarus exclusive rights in the U.S. to commercialize Type II diabetes drug Cycloset bromocriptine. The timed-release tablet was approved last year, but has not yet been marketed. VeroScience and S2 said at the time that they planned to sublicense marketing rights to a third party. Santarus plans to launch the product in November. ...